Sam Brusco, Associate Editor01.19.22
Smith+Nephew has acquired Engage Surgical, which owns the only commercially available cementless partial knee system in the U.S. The acquisition’s value is up to $135 million, based on sales performance.
The modern cementless knee implant serves a segment drive by potential for long-tern fixation via biologic integration, shorter operating times, and the shift to Ambulatory Surgery Centers (ASCs).
"Smith+Nephew is now the only medical device company offering both cemented and cementless partial knee implants in the US, as well as robotics-assistance through the CORI Surgical System that is well-suited for the precise alignment needed,” Randy Kilburn, Executive Vice President & General Manager, Reconstruction, Robotics and Digital at Smith+Nephew told the press. “Through our Sports Medicine franchise we have an established, strong position in ASCs where the vast majority of partial knees in the US are performed. Our VISIONAIRE business, the high performance and small footprint of CORI, plus our partial knee portfolio, is a unique compelling offering for customers."
The buy bolsters S+N’s Robotics and Real Intelligence strategy—partial knee surgeries are a good fit for robotics due to a need for precise alignment. S+N’s CORI Surgical System already supports the company’s JOURNEY II cemented unicompartmental knee, and the Engage Surgical Partial Knee System is optimized for robotics. It will have an application with CORI in the future.
"The Engage Surgical Team is excited about joining Smith+Nephew to help expand the impact of the Engage Surgical Partial Knee System and integrating it with the CORI Surgical System,” commented Engage Surgical CEO Dan Justin. “Smith+Nephew is well-suited and well-prepared to continue our mission of providing better outcomes for knee arthroplasty patients."
Engage Surgical’s partial knee has U.S. regulatory clearance and is in limited market release there.
The modern cementless knee implant serves a segment drive by potential for long-tern fixation via biologic integration, shorter operating times, and the shift to Ambulatory Surgery Centers (ASCs).
"Smith+Nephew is now the only medical device company offering both cemented and cementless partial knee implants in the US, as well as robotics-assistance through the CORI Surgical System that is well-suited for the precise alignment needed,” Randy Kilburn, Executive Vice President & General Manager, Reconstruction, Robotics and Digital at Smith+Nephew told the press. “Through our Sports Medicine franchise we have an established, strong position in ASCs where the vast majority of partial knees in the US are performed. Our VISIONAIRE business, the high performance and small footprint of CORI, plus our partial knee portfolio, is a unique compelling offering for customers."
The buy bolsters S+N’s Robotics and Real Intelligence strategy—partial knee surgeries are a good fit for robotics due to a need for precise alignment. S+N’s CORI Surgical System already supports the company’s JOURNEY II cemented unicompartmental knee, and the Engage Surgical Partial Knee System is optimized for robotics. It will have an application with CORI in the future.
"The Engage Surgical Team is excited about joining Smith+Nephew to help expand the impact of the Engage Surgical Partial Knee System and integrating it with the CORI Surgical System,” commented Engage Surgical CEO Dan Justin. “Smith+Nephew is well-suited and well-prepared to continue our mission of providing better outcomes for knee arthroplasty patients."
Engage Surgical’s partial knee has U.S. regulatory clearance and is in limited market release there.